Eluxadoline Patent Expiration
Eluxadoline is Used for reducing abdominal pain and diarrhea in patients with irritable bowel syndrome with diarrhea (IBS-D) with eluxadoline. It was first introduced by Abbvie Inc
Eluxadoline Patents
Given below is the list of patents protecting Eluxadoline, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Viberzi | US10188632 | Opioid receptor modulator dosage formulations | Mar 14, 2033 | Abbvie |
| Viberzi | US11007179 | Opioid receptor modulator dosage formulations | Mar 14, 2033 | Abbvie |
| Viberzi | US11090291 | Opioid receptor modulator dosage formulations | Mar 14, 2033 | Abbvie |
| Viberzi | US11160792 | Opioid receptor modulator dosage formulations | Mar 14, 2033 | Abbvie |
| Viberzi | US11229627 | Opioid receptor modulator dosage formulations | Mar 14, 2033 | Abbvie |
| Viberzi | US11311516 | Opioid receptor modulator dosage formulations | Mar 14, 2033 | Abbvie |
| Viberzi | US11484527 | Opioid receptor modulator dosage formulations | Mar 14, 2033 | Abbvie |
| Viberzi | US9675587 | Opioid receptor modulator dosage formulations | Mar 14, 2033 | Abbvie |
| Viberzi | US7741356 | Compounds as opioid receptor modulators | May 27, 2029 | Abbvie |
| Viberzi | US8691860 | Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid | Jul 07, 2028 | Abbvie |
| Viberzi | US9115091 | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid | Jul 07, 2028 | Abbvie |
| Viberzi | US9364489 | Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid | Jul 07, 2028 | Abbvie |
| Viberzi | US9789125 | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid | Jul 07, 2028 | Abbvie |
| Viberzi | US10213415 | Compounds as opioid receptor modulators | Mar 14, 2025 | Abbvie |
| Viberzi | US7786158 | Compounds as opioid receptor modulators | Mar 14, 2025 | Abbvie |
| Viberzi | US8344011 | Compounds as opioid receptor modulators | Mar 14, 2025 | Abbvie |
| Viberzi | US8609709 | Compounds as opioid receptor modulators | Mar 14, 2025 | Abbvie |
| Viberzi | US8772325 | Compounds as opioid receptor modulators | Mar 14, 2025 | Abbvie |
| Viberzi | US9205076 | Compounds as opioid receptor modulators | Mar 14, 2025 | Abbvie |
| Viberzi | US9700542 | Compounds as opioid receptor modulators | Mar 14, 2025 | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Eluxadoline's patents.
Latest Legal Activities on Eluxadoline's Patents
Given below is the list recent legal activities going on the following patents of Eluxadoline.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jun, 2024 | US8344011 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 May, 2023 | US9205076 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Jan, 2023 | US9115091 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Nov, 2022 | US11484527 |
| Recordation of Patent Grant Mailed Critical | 01 Nov, 2022 | US11484527 |
| Email Notification Critical | 13 Oct, 2022 | US11484527 |
| Issue Notification Mailed Critical | 12 Oct, 2022 | US11484527 |
| Dispatch to FDC | 28 Sep, 2022 | US11484527 |
| Application Is Considered Ready for Issue Critical | 28 Sep, 2022 | US11484527 |
| Issue Fee Payment Verified Critical | 27 Sep, 2022 | US11484527 |
Eluxadoline's Family Patents
